Good evening :)
Switch to
Place Order

Aurobindo Pharma Ltd

AUROPHARMA
Health CarePharmaceuticals
MidcapWith a market cap of ₹26,736 cr, stock is ranked 176
Low RiskStock is 1.90x as volatile as Nifty
464.051.70% (+7.75)
Investment Checklist
BasicPro
Go pro! Unlock deeper insights
Health CarePharmaceuticals
MidcapWith a market cap of ₹26,736 cr, stock is ranked 176
Low RiskStock is 1.90x as volatile as Nifty

Key Metrics

PE RatioPE RatioPB RatioPB RatioDividend YieldDiv. Yield
10.101.091.97%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
35.694.330.89%

Forecast & RatingsDetailed Forecast 

72%

Analysts have suggested that investors can buy this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Aurobindo Pharma Limited is an India-based pharmaceutical company. The Company develops, manufactures and distributes generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients. Its product portfolio is spread over seven therapeutic/product areas encompassing central nervous systems (CNS), anti-retroviral, cardiovascular (CVS), antibiotics, gastroenterological, anti-diabetics and anti-allergic. It is engaged in developing a range of oncology and hormonal products. It is developing topical as well as transdermal products in the dermatology therapeutic segment. It is also developing about three depot injections based on the microsphere and nano-suspension technology platforms. The Company is marketing its products globally in approximately 150 countries. The Company's subsidiaries include APL Healthcare Limited, Auronext Pharma Private Limited, Auro Peptides Limited, APL Pharma Thai Limited and Aurolife Pharma LLC, among others.

Brands

Aurobindo Pharma

Pharmaceutical company

Investor PresentationView older 

Nov 12, 2022

PDF
View Older Presentations

Brands

Aurobindo Pharma

Pharmaceutical company

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Financial TrendFinancial statements 

2019202020212022+19.72+23.29+28.40+23.89+2.36+2.85+5.33+2.65
Revenue
Profit
All values in ₹ Thousand cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent EventsAll events 

Press Release 
Announced OnNov 23, 2022

We enclose a copy of the Press Release issued by Acrotech Biopharma LLC, a step-down wholly owned subsidiary of the Company on entering into a license agreement with Evive Biotech to commercialize Ryzneuta¬トᄁ Ryzneuta¬トᄁ Ryzneuta¬トᄁ Ryzneuta¬トᄁ Ryzneuta¬トᄁ Ryzneuta¬トᄁ (Efbemalenograstim alfa) in the US in the US in the US in the US. | Download

We enclose a copy of the Press Release issued by Acrotech Biopharma LLC, a step-down wholly owned subsidiary of the Company on entering into a license agreement with Evive Biotech to commercialize Ryzneuta¬トᄁ Ryzneuta¬トᄁ Ryzneuta¬トᄁ Ryzneuta¬トᄁ Ryzneuta¬トᄁ Ryzneuta¬トᄁ (Efbemalenograstim alfa) in the US in the US in the US in the US. | Download

Schedule of Analysts/Institutional Investor Meet/Con. Call 
Announced OnNov 22, 2022

This is to inform you that Mr. S. Subramanian, Chief Financial Officer of the Company will be interacting today, November 22, 2022, between 12:00 p.m to 1:00 p.m with the officials of ICICI Prudential Life Insurance Company through virtual mode.No unpublished price sensitive information (UPSI) is intended to be discussed during the interactions.This intimation is submitted pursuant to Regulation 30(6) of the Listing Regulations. | Download

This is to inform you that Mr. S. Subramanian, Chief Financial Officer of the Company will be interacting today, November 22, 2022, between 12:00 p.m to 1:00 p.m with the officials of ICICI Prudential Life Insurance Company through virtual mode.No unpublished price sensitive information (UPSI) is intended to be discussed during the interactions.This intimation is submitted pursuant to Regulation 30(6) of the Listing Regulations. | Download

Cash Dividend 
Ex. DateJun 6, 2022

Interim 4 • Div/Share: ₹ 4.5

See all events